Independently scored across 5 dimensions · Updated weekly · No paid placements
Drug profile · Updated 12 May 2026

Wegovy (semaglutide): the 2026 buyer's guide

Wegovy is Novo Nordisk's once-weekly semaglutide injection, approved by the FDA in 2021 as the first GLP-1 specifically indicated for chronic weight management. Below: how it works, what trials show, what it costs in 2026, and which programs in our chart prescribe it.

Active ingredient
semaglutide
Manufacturer
Novo Nordisk
FDA-approved for
chronic weight management (2021)
Schedule
Weekly · subcutaneous injection (pre-filled pen)

Who it's for

Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea).

What the trials show

Wegovy's registration trial was STEP-1 (NEJM, 2021). At 68 weeks at the maximum dose, mean weight loss was 14.9% (12.4 percentage points greater than placebo). 86.4% of patients lost at least 5% of body weight; 50.5% lost at least 15%. Real-world results vary; trial patients are typically more adherent and more closely managed than typical telehealth patients.

Dose schedule

Dose levels: 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg. Standard practice is to titrate up monthly, holding at any tolerated dose. Maximum dose is 2.4mg weekly; many patients reach goal weight at sub-maximum doses and stay there.

What it costs in 2026

Retail cash (no insurance, no DTC)$1,349/mo
Manufacturer DTC (cash-pay direct)$199-$499/mo via NovoCare
With insurance + prior authorization$25-$50/mo with prior authorization
Compounded version (503A pharmacy)$99-$249/mo via 503A pharmacies

Telehealth programs add a membership fee on top of the medication cost (typically $40-$200/mo). For all-in monthly costs by program, see the chart.

Common side effects

The most commonly reported side effects in the registration trial:

Boxed warning: Risk of thyroid C-cell tumors (rodent data); contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

How Wegovy differs from related drugs

Same molecule as Ozempic and Rybelsus, branded specifically for weight loss at higher doses than the diabetes formulations.

Compounded semaglutide

Compounded semaglutide is the same active molecule prepared by a 503A pharmacy under prescription rather than manufactured under FDA new-drug approval as Wegovy. Cash-pay savings versus branded Wegovy are typically 50-80%, but the regulatory environment has tightened. FDA shortage list resolved October 2024; compounded semaglutide enforcement increased through 2025. For the comparison, see compounded vs FDA-approved semaglutide.

Programs that prescribe Wegovy

These programs in our chart prescribe Wegovy (with insurance coverage where applicable, or as a cash-pay option). Ranked by overall score.

Wegovy vs other GLP-1s

Editorial disclosure

GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Talk to a licensed clinician about whether Wegovy is appropriate for you. Pricing reflects publicly verified rates as of 12 May 2026; verify with the manufacturer or your prescriber before committing.

Why you can trust GLP Chart Same scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each provider's public-facing page weekly.
Independent comparison site. Not a medical provider, telehealth platform, or pharmacy. Information is educational, not medical advice. Always consult a licensed clinician. We may earn a commission on partner links at no cost to you.